- Home
- GMM vs EPIX Comparison
GMM vs EPIX Comparison
Compare GMM & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMM
- EPIX
- Stock Information
- Founded
- GMM 2017
- EPIX 2009
- Country
- GMM China
- EPIX Canada
- Employees
- GMM N/A
- EPIX N/A
- Industry
- GMM
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- GMM
- EPIX Health Care
- Exchange
- GMM Nasdaq
- EPIX Nasdaq
- Market Cap
- GMM 70.8M
- EPIX 75.9M
- IPO Year
- GMM 2023
- EPIX N/A
- Fundamental
- Price
- GMM $2.54
- EPIX $1.72
- Analyst Decision
- GMM
- EPIX Hold
- Analyst Count
- GMM 0
- EPIX 3
- Target Price
- GMM N/A
- EPIX $2.00
- AVG Volume (30 Days)
- GMM 14.3K
- EPIX 56.4K
- Earning Date
- GMM 07-11-2025
- EPIX 08-04-2025
- Dividend Yield
- GMM N/A
- EPIX N/A
- EPS Growth
- GMM 62.17
- EPIX N/A
- EPS
- GMM 6.37
- EPIX N/A
- Revenue
- GMM $41,360,953.00
- EPIX N/A
- Revenue This Year
- GMM N/A
- EPIX N/A
- Revenue Next Year
- GMM N/A
- EPIX N/A
- P/E Ratio
- GMM $0.40
- EPIX N/A
- Revenue Growth
- GMM 53.82
- EPIX N/A
- 52 Week Low
- GMM $1.69
- EPIX $1.40
- 52 Week High
- GMM $15.60
- EPIX $7.88
- Technical
- Relative Strength Index (RSI)
- GMM 40.95
- EPIX 58.15
- Support Level
- GMM $2.77
- EPIX $1.60
- Resistance Level
- GMM $2.73
- EPIX $1.73
- Average True Range (ATR)
- GMM 0.14
- EPIX 0.04
- MACD
- GMM -0.04
- EPIX 0.00
- Stochastic Oscillator
- GMM 14.40
- EPIX 88.89
About GMM Global Mofy Metaverse Limited
Global Mofy AI Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital assets development for the metaverse industry. It utilizes its proprietary Mofy Lab technology platform which consists of three-dimensional (3D) rebuilt technology and artificial intelligence (AI) interactive technology to create a 3D high-definition virtual version of a wide range of physical world objects such as human, animal, and scenes which can be used in different applications.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.